Latanoprost Viatris

Latanoprost, the active ingredient in Latanoprost Viatris, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intraocular pressure in patients with glaucoma or ocular hypertension. GNH USA supplies Latanoprost Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intraocular pressure. - Elevated intraocular pressure: reduces pressure to prevent optic nerve damage. - Open-angle glaucoma: helps preserve visual field by lowering pressure. - Ocular hypertension: maintains normal pressure levels to reduce risk of glaucoma development.

Latanoprost may cause ocular and peri‑ocular reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eyelash growth: increased length and thickness. - Iris pigmentation: gradual darkening of the iris. - Eye irritation: burning or stinging sensation. - Blurred vision: transient visual disturbance. - Dry eye: reduced tear film stability.

Serious or Rare Side Effects: - Paradoxical increase in intraocular pressure. - Uveitis: inflammation of the uveal tract. - Corneal edema: swelling of the cornea. - Severe allergic reaction: swelling, itching, or rash. - Significant eye pain: may indicate underlying complication. - Vision loss: rare but requires immediate medical attention.

Before initiating Latanoprost, clinicians should evaluate patient suitability and monitor for adverse events. - Assess baseline intraocular pressure: ensure appropriate therapeutic target. - Monitor iris color changes: inform patients of possible permanent pigmentation. - Avoid use during active ocular inflammation: may exacerbate condition. - Counsel on eyelash growth: discuss cosmetic implications. - Do not combine with other prostaglandin analog eye drops: risk of additive side effects. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents that affect intraocular pressure or ocular health.

Major Interactions (Avoid): - Concurrent prostaglandin analog eye drops: increased risk of ocular irritation and pigment changes. - Systemic carbonic anhydrase inhibitors: additive pressure‑lowering effect may lead to hypotony. - Recent ocular surgery: may impair wound healing.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: potential for excessive intraocular pressure reduction. - Alpha‑agonist eye drops: may enhance pressure‑lowering effect. - Topical corticosteroids: could diminish Latanoprost efficacy.